Second Most Fatal Cancer In U.S. To Face A Challenger: Mainz Biomed's ($MYNZ) Early Detection Tech

With the creation of ColoAlert, easier and more accessible cancer screenings for quick detection and treatment of colorectal cancer are possible.

Mainz Biomed (NASDAQ: $MYNZ), specializes in developing molecular genetic diagnostic solutions for life-threatening conditions. With the creation of ColoAlert, easier and more accessible cancer screenings for quick detection and treatment of colorectal cancer are possible.

see more: https://youtu.be/06-tmZONy7Y

https://ift.tt/QGIdgej Submitted September 01, 2023 at 03:48PM by a8k002ncdr https://ift.tt/Fe0NDBL